Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Dose-Ranging Trial Of Novavax Pandemic Flu Vaccine Demonstrates Immunogenicity

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm says further development of vaccine for Indonesia 2005 strain requires either co-development partner or government contracts.

You may also be interested in...



PIPE Proceeds In Hand, Novavax Looks To Score With Two Late-Stage Flu Vaccines

Vaccine-focused biotech says it has sufficient cash to continue business strategy through third-quarter 2009.

PIPE Proceeds In Hand, Novavax Looks To Score With Two Late-Stage Flu Vaccines

Vaccine-focused biotech says it has sufficient cash to continue business strategy through third-quarter 2009.

FDA Starts Process For Regulating Next-generation Vaccine Adjuvants

Scientific meeting planned for late fall or early spring.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

See All
UsernamePublicRestriction

Register

PS068273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By